Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitinib in Severe Aplastic Anemia
NCT07297550Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of golidocitinib in aplastic anemia (3 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Incidence and severity of adverse events at 12 weeks and Complete hematological response at 3 months. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
golidocitinib
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT07297550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07297550.